サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1804880

抗がん剤：市場規模と予測 (2021～2031年)、世界・地域シェア、動向、成長機会 - 分析範囲 (治療法の種類別、適応症別、流通チャネル別、地域別)

Cancer Drugs Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Therapy Type, By Indications, By Distribution Channel, and Geography

出版日
ページ情報
英文 277 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.52円
抗がん剤：市場規模と予測 (2021～2031年)、世界・地域シェア、動向、成長機会 - 分析範囲 (治療法の種類別、適応症別、流通チャネル別、地域別)
出版日: 2025年08月06日
発行: The Insight Partners
ページ情報: 英文 277 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗がん剤市場は、2024年の2,259億6,000万米ドルから2031年には5,161億5,000万米ドルに達すると予測されています。2025～2031年のCAGRは12.6%と推定されます。市場成長を促進する主な要因としては、乳がんや肺がんの負担が増加していること、腫瘍学研究への投資が急増していることなどが挙げられ、抗がん剤の採用を後押ししています。さらに、個別化医療への嗜好が予測期間中に市場を押し上げる可能性が高いです。しかし、治療費の高さは市場阻害要因のひとつです。

肺がんの負担増は、特に2023年の抗がん剤市場の重要な促進要因です。肺がんは依然として世界的に最も罹患率が高く、死亡率の高いがんのひとつであり、がんによる死亡者数の25%を占めています。米国がん協会によると、2023年には米国で推定23万8,000人が新たに肺がんと診断され、12万7,000人が肺がんで死亡しました。症例の半数近くが遠隔（転移性）ステージで診断され、5年生存率は29％に低下します。この厳しい統計は、効果的な治療オプションの差し迫った必要性を強調し、革新的な治療薬への需要を煽っています。喫煙は依然として罹患者の約85％を占める主要な危険因子ですが、特にWHOの大気質基準を下回る地域では、大気汚染が主な原因となって非喫煙者の肺がん罹患率が上昇しています。非喫煙者における罹患率の増加は、腺がんやタバコへの曝露とは直接関係のない他のサブタイプを標的とした、より広く適用可能な治療に対するアンメットニーズを際立たせています。

早期発見と精密医療における課題は、この増大する課題に取り組む上で極めて重要です。標的治療、免疫療法、併用療法の開発は、生存率と生活の質を改善します。2023年には、EGFR変異型NSCLCに対するタグリッソ（オシメルチニブ）などの新薬の承認や、新規免疫チェックポイント阻害薬の臨床試験が進行中であり、引き続き治療情勢が再構築されます。免疫療法は有望な結果を示しており、キイトルーダ（ペムブロリズマブ）やオプジーボ（ニボルマブ）などの薬剤は、がんと闘うために身体の免疫系を利用することで患者の転帰を著しく改善しています。したがって、乳がんの罹患率の増加が世界の抗がん剤市場の成長を牽引しています。さらに、国民のがんに対する意識の高まりは、この市場の開拓にプラスに寄与すると予想されます。

競合企業比較分析では、製品ポートフォリオ（製品満足度、製品特徴、入手可能性）、最近の市場動向（合併・買収、新製品発売・強化、投資・資金調達、受賞、合意、提携・協力、認知、拡大）、競合情勢のより良い意思決定と理解を助ける地域的存在に基づいて、抗がん剤市場を評価・分類しています。本レポートでは、世界の抗がん剤市場における主要ベンダーの最近の重要な動向と革新について深く調査しています。主な市場プレイヤーは、ブリストル・マイヤーズスクイブ社、アッヴィ社、ジョンソン・エンド・ジョンソン社、F.ホフマン・ラ・ロシュ社、ファイザー社、アストラゼネカ社、メルクKGaA社、ノバルティス社、アステラス製薬社、イーライリリー・アンド・カンパニー社です。

抗がん剤市場は、治療法の種類によって、化学療法、標的療法、放射線療法、ホルモン療法、その他の治療法に区分されます。2024年には、標的療法分野が抗がん剤市場で最大のシェアを占めています。

適応症別では、血液がん、肺がん、乳がん、大腸がん、前立腺がん、胃がん、子宮頸がん、肝・肝内胆管がん、甲状腺がん、その他の適応症に区分されます。乳がん分野は2024年に抗がん剤市場で最大のシェアを占め、2025年から2031年にかけて最も高いCAGRを記録すると予測されています。乳がんは最も罹患率の高いがんのひとつであり、世界全体で毎年230万人が新たにがんと診断されると推定されています。乳がんは女性における主要ながんであり、世界中でがん関連死亡の主な原因となっています。しかし、乳がんの研究と治療における著しい進歩により、特に早期診断における生存率は劇的に改善しました。標的療法、免疫療法、個別化治療レジメンの開発により、乳がんの治療状況は変化し続けています。

流通経路の観点から、抗がん剤市場は病院薬局、小売薬局、オンラインストアに区分されます。病院薬局セグメントは2024年に抗がん剤市場で最大のシェアを占め、2025年から2031年にかけて最も高いCAGRを記録すると予測されています。

抗がん剤市場で事業を展開する企業は、有機的および無機的なさまざまな戦略を採用しています。有機的戦略には主に、製品上市や製品承認が含まれます。市場で見られる無機的成長戦略には、買収、提携、パートナーシップなどがあります。これらの成長戦略により、市場プレーヤーは事業を拡大し、地理的プレゼンスを高め、市場全体の成長に貢献することができます。さらに、買収や提携は、顧客基盤の強化や製品ポートフォリオの拡大に役立っています。抗がん剤市場における主要企業の重要な発展の一部を以下に示します。

2024年、米国とカナダ以外ではMSDとして知られるメルクと、非上場企業であるLaNova Medicines Ltd.（LaNova）が合併します。（LaNova）は、メルクがLaNovaの新規PD-1/VEGF二重特異性抗体LM-299の開発、製造、商業化に関する独占的グローバルライセンスを締結したと発表しました。

2024年、中国国家薬品監督管理局が、進行膀胱がんのファーストライン治療におけるKEYTRUDA（ペムブロリズマブ）と併用するenfortumab vedotinに関するアステラス製薬とファイザー社の生物製剤追加承認申請を受理。

2023年、ファイザー社は、革新的な抗がん剤の発見、開発、商業化を行う世界的なバイオテクノロジー企業であるシーゲン社の買収が成功裏に完了したことを発表しました。ファイザーは、シーゲンの発行済普通株式すべてを1株当たり米国現金229米ドルで取得し、企業価値合計約430億米ドルの買収を完了しました。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要洞察
  • 市場の魅力

第3章 分析手法

  • 二次調査
  • 一次調査
    • 仮説の策定
    • マクロ経済要因分析
    • 基礎数値の動向
    • データの三角測量
    • 国レベルのデータ
  • 仮定と限界

第4章 抗がん剤市場の情勢

  • PEST分析
  • エコシステム分析
    • バリューチェーンのベンダー一覧

第5章 抗がん剤市場：主な市場力学

  • 抗がん剤市場：主な市場力学
  • 市場促進要因
    • 乳がん・肺がんの負担増
    • オンコロジー研究への投資の急増
  • 市場抑制要因
    • 治療費の高騰
  • 市場機会
    • 政府および民間団体からの支援の増加
  • 今後の動向
    • 個別化医療への嗜好
  • 促進要因と抑制要因の影響

第6章 抗がん剤市場：世界市場の分析

  • 抗がん剤市場の収益 (2021～2031年)
  • 抗がん剤市場の予測・分析

第7章 抗がん剤市場の分析：治療法の種類別

  • 化学療法
  • 標的療法
  • 免疫療法
  • ホルモン療法
  • その他の治療法の種類

第8章 抗がん剤市場の分析：適応症別

  • 血液がん
  • 肺がん
  • 乳がん
  • 大腸がん
  • 前立腺がん
  • 胃がん
  • 子宮頸がん
  • 肝臓がん・肝内胆管がん
  • 甲状腺がん
  • その他の適応症

第9章 抗がん剤市場の分析：流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンラインストア

第10章 抗がん剤市場：地域別分析

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • その他のアジア太平洋
  • 中東・アフリカ
    • トルコ
    • GCC諸国
    • 南アフリカ
    • その他中東・アフリカ
  • 中南米
    • ブラジル
    • アルゼンチン
    • その他中南米

第11章 競合情勢

  • ヒートマップ分析：主要企業別
  • 企業のポジショニングと集中度

第12章 業界情勢

  • 市場イニシアティブ
  • パートナーシップと提携
  • その他の動向

第13章 企業プロファイル

  • Bristol-Myers Squibb Co
  • AbbVie Inc
  • Astellas Pharma Inc
  • Eli Lilly and Co
  • Novartis AG
  • Merck KGaA
  • AstraZeneca
  • Pfizer Inc
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson

第14章 付録

図表

List Of Tables

  • Table 1. Cancer Drugs Market Segmentation
  • Table 2. List of Vendors
  • Table 3. Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million)
  • Table 4. Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Therapy Types
  • Table 5. Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Indications
  • Table 6. Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Distribution Channel
  • Table 7. North America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Therapy Types
  • Table 8. North America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Indications
  • Table 9. North America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Distribution Channel
  • Table 10. North America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 11. United States: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 12. United States: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 13. United States: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 14. Canada: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 15. Canada: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 16. Canada: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 17. Mexico: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 18. Mexico: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 19. Mexico: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 20. Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Therapy Types
  • Table 21. Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Indications
  • Table 22. Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Distribution Channel
  • Table 23. Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 24. Germany: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 25. Germany: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 26. Germany: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 27. United Kingdom: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 28. United Kingdom: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 29. United Kingdom: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 30. France: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 31. France: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 32. France: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 33. Italy: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 34. Italy: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 35. Italy: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 36. Spain: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 37. Spain: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 38. Spain: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 39. Rest of Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 40. Rest of Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 41. Rest of Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 42. Asia Pacific: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Therapy Types
  • Table 43. Asia Pacific: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Indications
  • Table 44. Asia Pacific: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Distribution Channel
  • Table 45. Asia Pacific: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 46. China: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 47. China: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 48. China: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 49. Japan: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 50. Japan: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 51. Japan: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 52. India: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 53. India: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 54. India: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 55. South Korea: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 56. South Korea: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 57. South Korea: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 58. Australia: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 59. Australia: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 60. Australia: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 61. Rest of APAC: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 62. Rest of APAC: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 63. Rest of APAC: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 64. Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Therapy Types
  • Table 65. Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Indications
  • Table 66. Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Distribution Channel
  • Table 67. Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 68. Turkey: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 69. Turkey: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 70. Turkey: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 71. GCC Countries: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 72. GCC Countries: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 73. GCC Countries: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 74. South Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 75. South Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 76. South Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 77. Rest of Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 78. Rest of Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 79. Rest of Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 80. South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Therapy Types
  • Table 81. South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Indications
  • Table 82. South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Distribution Channel
  • Table 83. South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 84. Brazil: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 85. Brazil: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 86. Brazil: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 87. Argentina: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 88. Argentina: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 89. Argentina: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 90. Rest of South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Therapy Types
  • Table 91. Rest of South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Indications
  • Table 92. Rest of South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million) - by Distribution Channel
  • Table 93. List of Abbreviations

List Of Figures

  • Figure 1. Cancer Drugs Market Segmentation - Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Cancer Drugs Market Revenue (US$ Million), 2021-2031
  • Figure 5. Cancer Drugs Market Share (%) - by Therapy Types (2024 and 2031)
  • Figure 6. Chemotherapy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 7. Targeted Therapy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 8. Immunotherapy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 9. Hormonal Therapy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 10. Other Therapy Types: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 11. Cancer Drugs Market Share (%) - by Indications (2024 and 2031)
  • Figure 12. Blood Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 13. Lung Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 14. Breast Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 15. Colorectal Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 16. Prostate Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 17. Stomach Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 18. Cervical Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 19. Liver and Intrahepatic Bile Ducts Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 20. Thyroid Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 21. Other Indications: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 22. Cancer Drugs Market Share (%) - by Distribution Channel (2024 and 2031)
  • Figure 23. Hospital Pharmacies: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 24. Retail Pharmacies: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 25. Online Stores: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 26. Cancer Drugs Market Regional Share, 2024 and 2031 (%)
  • Figure 27. North America: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million)
  • Figure 28. North America: Cancer Drugs Market Share - by Therapy Types (2024 and 2031)
  • Figure 29. North America: Cancer Drugs Market Share - by Indications (2024 and 2031)
  • Figure 30. North America: Cancer Drugs Market Share - by Distribution Channel (2024 and 2031)
  • Figure 31. North America: Cancer Drugs Market Share - Key Countries, 2024 and 2031 (%)
  • Figure 32. United States: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 33. Canada: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 34. Mexico: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 35. Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million)
  • Figure 36. Europe: Cancer Drugs Market Share - by Therapy Types (2024 and 2031)
  • Figure 37. Europe: Cancer Drugs Market Share - by Indications (2024 and 2031)
  • Figure 38. Europe: Cancer Drugs Market Share - by Distribution Channel (2024 and 2031)
  • Figure 39. Europe: Cancer Drugs Market Share - Key Countries, 2024 and 2031 (%)
  • Figure 40. Germany: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 41. United Kingdom: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 42. France: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 43. Italy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 44. Spain: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 45. Rest of Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 46. Asia Pacific: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million)
  • Figure 47. Asia Pacific: Cancer Drugs Market Share - by Therapy Types (2024 and 2031)
  • Figure 48. Asia Pacific: Cancer Drugs Market Share - by Indications (2024 and 2031)
  • Figure 49. Asia Pacific: Cancer Drugs Market Share - by Distribution Channel (2024 and 2031)
  • Figure 50. Asia Pacific: Cancer Drugs Market Share - Key Countries, 2024 and 2031 (%)
  • Figure 51. China: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 52. Japan: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 53. India: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 54. South Korea: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 55. Australia: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 56. Rest of APAC: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 57. Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million)
  • Figure 58. Middle East and Africa: Cancer Drugs Market Share - by Therapy Types (2024 and 2031)
  • Figure 59. Middle East and Africa: Cancer Drugs Market Share - by Indications (2024 and 2031)
  • Figure 60. Middle East and Africa: Cancer Drugs Market Share - by Distribution Channel (2024 and 2031)
  • Figure 61. Middle East and Africa: Cancer Drugs Market Share - Key Countries, 2024 and 2031 (%)
  • Figure 62. Turkey: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 63. GCC Countries: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 64. South Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 65. Rest of Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 66. South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031(US$ Million)
  • Figure 67. South and Central America: Cancer Drugs Market Share - by Therapy Types (2024 and 2031)
  • Figure 68. South and Central America: Cancer Drugs Market Share - by Indications (2024 and 2031)
  • Figure 69. South and Central America: Cancer Drugs Market Share - by Distribution Channel (2024 and 2031)
  • Figure 70. South and Central America: Cancer Drugs Market Share - Key Countries, 2024 and 2031 (%)
  • Figure 71. Brazil: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 72. Argentina: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 73. Rest of South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 74. Heat Map Analysis by Key Players
  • Figure 75. Company Positioning and Concentration
目次
Product Code: TIPRE00040984

The cancer drugs market is projected to reach US$ 516.15 billion by 2031 from US$ 225.96 billion in 2024. The market is estimated to register a CAGR of 12.6% during 2025-2031. Major factors driving the market growth include a growing burden of breast and lung cancer, and surging investments in oncology research are propelling the adoption of cancer drugs. Further, the preference for personalized medicine will likely boost the market during the forecast period. However, the high cost of treatment is among the market deterrents.

The growing burden of lung cancer is a significant driver of the cancer drugs market, particularly in 2023. Lung cancer remains one of the most prevalent and deadly cancers globally, accounting for ~25% of all cancer deaths. According to the American Cancer Society, in 2023, an estimated 238,000 new cases of lung cancer were diagnosed in the US, and ~127,000 people died from the disease. Nearly half of the cases are diagnosed at distant (metastatic) stages, where survival drops to a 29% five-year survival, underscoring the critical demand for more effective therapeutic options. This grim statistic underscores the pressing need for effective treatment options and fuels the demand for innovative therapeutics. Although smoking remains the leading risk factor responsible for ~85% of cases, there is a rising share of lung cancer among never-smokers, driven primarily by air pollution, particularly in regions below WHO air quality standards. The increasing incidence among non-smokers accentuates the unmet need for more widely applicable treatments targeting adenocarcinoma and other subtypes not directly linked to tobacco exposure.

Advancements in early detection and precision medicine are pivotal in addressing this growing challenge. Developing targeted therapies, immunotherapies, and combination treatments improves survival rates and quality of life. In 2023, the approval of new drugs such as Tagrisso (osimertinib) for EGFR-mutant NSCLC and the ongoing clinical trials of novel immune checkpoint inhibitors continue to reshape the therapeutic landscape. Immunotherapy has shown promising results, with drugs such as Keytruda (pembrolizumab) and Opdivo (nivolumab) significantly improving patient outcomes by harnessing the body's immune system to fight cancer. Therefore, the increasing incidence of breast cancer drives the global cancer drugs market growth. Additionally, the rising awareness of cancer among the population is expected to contribute positively to the development of this market.

The comparative company analysis evaluates and categorizes the Cancer Drugs market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global cancer drugs market. The key market players are Bristol-Myers Squibb Co.; AbbVie Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd; Pfizer Inc.; AstraZeneca Plc; Merck KGaA; Novartis AG; Astellas Pharma Inc.; and Eli Lilly and Co.

Based on therapy types, the cancer drugs market is segmented into chemotherapy, targeted therapy, radiation therapy, hormone therapy, and other therapy types. The targeted therapy segment held the largest cancer drugs market share in 2024.

By indications, the market is segmented into blood cancer, lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach cancer, cervical cancer, liver and intrahepatic bile ducts cancer, thyroid cancer, and other indications. The breast cancer segment held the largest share of the cancer drugs market in 2024 and is anticipated to register the highest CAGR from 2025 to 2031. Breast cancer is one of the most prevalent forms of cancer, with an estimated 2.3 million new cases diagnosed globally each year. It is the leading cancer in women and remains a prime cause of cancer-related mortality worldwide. However, significant advancements in breast cancer research and treatment have dramatically improved survival rates, particularly in early-stage diagnoses. Ongoing developments in targeted therapies, immunotherapies, and personalized treatment regimens continue to transform the therapeutic landscape for breast cancer.

In terms of distribution channel, the cancer drugs market is segmented into hospital pharmacies, retail pharmacies, and online stores. The hospital pharmacies segment held the largest share of the cancer drugs market in 2024 and is anticipated to register the highest CAGR during 2025-2031.

Companies operating in the cancer drugs market adopt various organic and inorganic strategies. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses, enhance their geographic presence, and contribute to the overall market growth. Furthermore, acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few of the significant developments by key players in the cancer drugs market are listed below.

In 2024, Merck, known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, announced that Merck had entered into an exclusive global license to develop, manufacture, and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova.

In 2024, China's National Medical Products Administration accepted Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer.

In 2023, Pfizer Inc. announced the successful completion of its acquisition of Seagen Inc., a global biotechnology company that discovers, develops, and commercializes transformative cancer medicines. Pfizer completed its acquisition of all outstanding common stock of Seagen for US$ 229 in cash per share, for a total enterprise value of approximately US$ 43 billion.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macroeconomic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country-level data:
  • 3.3 Assumptions and Limitations

4. Cancer Drugs Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in Value Chain

5. Cancer Drugs Market - Key Market Dynamics

  • 5.1 Cancer Drugs Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Growing Burden of Breast and Lung Cancer
    • 5.2.2 Surging Investments in Oncology Research
  • 5.3 Market Restraints
    • 5.3.1 High Cost of Treatment
  • 5.4 Market Opportunities
    • 5.4.1 Increased Support from Government and Private Organizations
  • 5.5 Future Trends
    • 5.5.1 Preference for Personalized Medicine
  • 5.6 Impact of Drivers and Restraints:

6. Cancer Drugs Market - Global Market Analysis

  • 6.1 Cancer Drugs Market Revenue (US$ Million), 2021-2031
  • 6.2 Cancer Drugs Market Forecast Analysis

7. Cancer Drugs Market Analysis - by Therapy Types

  • 7.1 Chemotherapy
    • 7.1.1 Overview
    • 7.1.2 Chemotherapy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.2 Targeted Therapy
    • 7.2.1 Overview
    • 7.2.2 Targeted Therapy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.3 Immunotherapy
    • 7.3.1 Overview
    • 7.3.2 Immunotherapy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.4 Hormonal Therapy
    • 7.4.1 Overview
    • 7.4.2 Hormonal Therapy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.5 Other Therapy Types
    • 7.5.1 Overview
    • 7.5.2 Other Therapy Types: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Cancer Drugs Market Analysis - by Indications

  • 8.1 Blood Cancer
    • 8.1.1 Overview
    • 8.1.2 Blood Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.2 Lung Cancer
    • 8.2.1 Overview
    • 8.2.2 Lung Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.3 Breast Cancer
    • 8.3.1 Overview
    • 8.3.2 Breast Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.4 Colorectal Cancer
    • 8.4.1 Overview
    • 8.4.2 Colorectal Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.5 Prostate Cancer
    • 8.5.1 Overview
    • 8.5.2 Prostate Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.6 Stomach Cancer
    • 8.6.1 Overview
    • 8.6.2 Stomach Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.7 Cervical Cancer
    • 8.7.1 Overview
    • 8.7.2 Cervical Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.8 Liver and Intrahepatic Bile Ducts Cancer
    • 8.8.1 Overview
    • 8.8.2 Liver and Intrahepatic Bile Ducts Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.9 Thyroid Cancer
    • 8.9.1 Overview
    • 8.9.2 Thyroid Cancer: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.10 Other Indications
    • 8.10.1 Overview
    • 8.10.2 Other Indications: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Cancer Drugs Market Analysis - by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Overview
    • 9.1.2 Hospital Pharmacies: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.2 Retail Pharmacies
    • 9.2.1 Overview
    • 9.2.2 Retail Pharmacies: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.3 Online Stores
    • 9.3.1 Overview
    • 9.3.2 Online Stores: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. Cancer Drugs Market - Geographical Analysis

  • 10.1 Overview
  • 10.2 North America
    • 10.2.1 North America Cancer Drugs Market Overview
    • 10.2.2 North America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    • 10.2.3 North America: Cancer Drugs Market Share - by Therapy Types
      • 10.2.3.1 North America: Cancer Drugs Market- Revenue and Forecast Analysis - by Therapy Types
    • 10.2.4 North America: Cancer Drugs Market Share - by Indications
      • 10.2.4.1 North America: Cancer Drugs Market- Revenue and Forecast Analysis - by Indications
    • 10.2.5 North America: Cancer Drugs Market Share - by Distribution Channel
      • 10.2.5.1 North America: Cancer Drugs Market- Revenue and Forecast Analysis - by Distribution Channel
    • 10.2.6 North America: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.2.6.1 North America: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.2.6.2 United States: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.2.6.2.1 United States: Cancer Drugs Market Share - by Therapy Types
        • 10.2.6.2.2 United States: Cancer Drugs Market Share - by Indications
        • 10.2.6.2.3 United States: Cancer Drugs Market Share - by Distribution Channel
      • 10.2.6.3 Canada: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.2.6.3.1 Canada: Cancer Drugs Market Share - by Therapy Types
        • 10.2.6.3.2 Canada: Cancer Drugs Market Share - by Indications
        • 10.2.6.3.3 Canada: Cancer Drugs Market Share - by Distribution Channel
      • 10.2.6.4 Mexico: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.2.6.4.1 Mexico: Cancer Drugs Market Share - by Therapy Types
        • 10.2.6.4.2 Mexico: Cancer Drugs Market Share - by Indications
        • 10.2.6.4.3 Mexico: Cancer Drugs Market Share - by Distribution Channel
  • 10.3 Europe
    • 10.3.1 Europe Cancer Drugs Market Overview
    • 10.3.2 Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    • 10.3.3 Europe: Cancer Drugs Market Share - by Therapy Types
      • 10.3.3.1 Europe: Cancer Drugs Market- Revenue and Forecast Analysis - by Therapy Types
    • 10.3.4 Europe: Cancer Drugs Market Share - by Indications
      • 10.3.4.1 Europe: Cancer Drugs Market- Revenue and Forecast Analysis - by Indications
    • 10.3.5 Europe: Cancer Drugs Market Share - by Distribution Channel
      • 10.3.5.1 Europe: Cancer Drugs Market- Revenue and Forecast Analysis - by Distribution Channel
    • 10.3.6 Europe: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.3.6.1 Europe: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.3.6.2 Germany: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.3.6.2.1 Germany: Cancer Drugs Market Share - by Therapy Types
        • 10.3.6.2.2 Germany: Cancer Drugs Market Share - by Indications
        • 10.3.6.2.3 Germany: Cancer Drugs Market Share - by Distribution Channel
      • 10.3.6.3 United Kingdom: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.3.6.3.1 United Kingdom: Cancer Drugs Market Share - by Therapy Types
        • 10.3.6.3.2 United Kingdom: Cancer Drugs Market Share - by Indications
        • 10.3.6.3.3 United Kingdom: Cancer Drugs Market Share - by Distribution Channel
      • 10.3.6.4 France: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.3.6.4.1 France: Cancer Drugs Market Share - by Therapy Types
        • 10.3.6.4.2 France: Cancer Drugs Market Share - by Indications
        • 10.3.6.4.3 France: Cancer Drugs Market Share - by Distribution Channel
      • 10.3.6.5 Italy: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.3.6.5.1 Italy: Cancer Drugs Market Share - by Therapy Types
        • 10.3.6.5.2 Italy: Cancer Drugs Market Share - by Indications
        • 10.3.6.5.3 Italy: Cancer Drugs Market Share - by Distribution Channel
      • 10.3.6.6 Spain: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.3.6.6.1 Spain: Cancer Drugs Market Share - by Therapy Types
        • 10.3.6.6.2 Spain: Cancer Drugs Market Share - by Indications
        • 10.3.6.6.3 Spain: Cancer Drugs Market Share - by Distribution Channel
      • 10.3.6.7 Rest of Europe: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.3.6.7.1 Rest of Europe: Cancer Drugs Market Share - by Therapy Types
        • 10.3.6.7.2 Rest of Europe: Cancer Drugs Market Share - by Indications
        • 10.3.6.7.3 Rest of Europe: Cancer Drugs Market Share - by Distribution Channel
  • 10.4 Asia Pacific
    • 10.4.1 Asia Pacific Cancer Drugs Market Overview
    • 10.4.2 Asia Pacific: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    • 10.4.3 Asia Pacific: Cancer Drugs Market Share - by Therapy Types
      • 10.4.3.1 Asia Pacific: Cancer Drugs Market- Revenue and Forecast Analysis - by Therapy Types
    • 10.4.4 Asia Pacific: Cancer Drugs Market Share - by Indications
      • 10.4.4.1 Asia Pacific: Cancer Drugs Market- Revenue and Forecast Analysis - by Indications
    • 10.4.5 Asia Pacific: Cancer Drugs Market Share - by Distribution Channel
      • 10.4.5.1 Asia Pacific: Cancer Drugs Market- Revenue and Forecast Analysis - by Distribution Channel
    • 10.4.6 Asia Pacific: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.4.6.1 Asia Pacific: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.4.6.2 China: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.4.6.2.1 China: Cancer Drugs Market Share - by Therapy Types
        • 10.4.6.2.2 China: Cancer Drugs Market Share - by Indications
        • 10.4.6.2.3 China: Cancer Drugs Market Share - by Distribution Channel
      • 10.4.6.3 Japan: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.4.6.3.1 Japan: Cancer Drugs Market Share - by Therapy Types
        • 10.4.6.3.2 Japan: Cancer Drugs Market Share - by Indications
        • 10.4.6.3.3 Japan: Cancer Drugs Market Share - by Distribution Channel
      • 10.4.6.4 India: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.4.6.4.1 India: Cancer Drugs Market Share - by Therapy Types
        • 10.4.6.4.2 India: Cancer Drugs Market Share - by Indications
        • 10.4.6.4.3 India: Cancer Drugs Market Share - by Distribution Channel
      • 10.4.6.5 South Korea: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.4.6.5.1 South Korea: Cancer Drugs Market Share - by Therapy Types
        • 10.4.6.5.2 South Korea: Cancer Drugs Market Share - by Indications
        • 10.4.6.5.3 South Korea: Cancer Drugs Market Share - by Distribution Channel
      • 10.4.6.6 Australia: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.4.6.6.1 Australia: Cancer Drugs Market Share - by Therapy Types
        • 10.4.6.6.2 Australia: Cancer Drugs Market Share - by Indications
        • 10.4.6.6.3 Australia: Cancer Drugs Market Share - by Distribution Channel
      • 10.4.6.7 Rest of APAC: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.4.6.7.1 Rest of APAC: Cancer Drugs Market Share - by Therapy Types
        • 10.4.6.7.2 Rest of APAC: Cancer Drugs Market Share - by Indications
        • 10.4.6.7.3 Rest of APAC: Cancer Drugs Market Share - by Distribution Channel
  • 10.5 Middle East and Africa
    • 10.5.1 Middle East and Africa Cancer Drugs Market Overview
    • 10.5.2 Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    • 10.5.3 Middle East and Africa: Cancer Drugs Market Share - by Therapy Types
      • 10.5.3.1 Middle East and Africa: Cancer Drugs Market- Revenue and Forecast Analysis - by Therapy Types
    • 10.5.4 Middle East and Africa: Cancer Drugs Market Share - by Indications
      • 10.5.4.1 Middle East and Africa: Cancer Drugs Market- Revenue and Forecast Analysis - by Indications
    • 10.5.5 Middle East and Africa: Cancer Drugs Market Share - by Distribution Channel
      • 10.5.5.1 Middle East and Africa: Cancer Drugs Market- Revenue and Forecast Analysis - by Distribution Channel
    • 10.5.6 Middle East and Africa: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.5.6.1 Middle East and Africa: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.5.6.2 Turkey: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.5.6.2.1 Turkey: Cancer Drugs Market Share - by Therapy Types
        • 10.5.6.2.2 Turkey: Cancer Drugs Market Share - by Indications
        • 10.5.6.2.3 Turkey: Cancer Drugs Market Share - by Distribution Channel
      • 10.5.6.3 GCC Countries: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.5.6.3.1 GCC Countries: Cancer Drugs Market Share - by Therapy Types
        • 10.5.6.3.2 GCC Countries: Cancer Drugs Market Share - by Indications
        • 10.5.6.3.3 GCC Countries: Cancer Drugs Market Share - by Distribution Channel
      • 10.5.6.4 South Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.5.6.4.1 South Africa: Cancer Drugs Market Share - by Therapy Types
        • 10.5.6.4.2 South Africa: Cancer Drugs Market Share - by Indications
        • 10.5.6.4.3 South Africa: Cancer Drugs Market Share - by Distribution Channel
      • 10.5.6.5 Rest of Middle East and Africa: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.5.6.5.1 Rest of Middle East and Africa: Cancer Drugs Market Share - by Therapy Types
        • 10.5.6.5.2 Rest of Middle East and Africa: Cancer Drugs Market Share - by Indications
        • 10.5.6.5.3 Rest of Middle East and Africa: Cancer Drugs Market Share - by Distribution Channel
  • 10.6 South and Central America
    • 10.6.1 South and Central America Cancer Drugs Market Overview
    • 10.6.2 South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
    • 10.6.3 South and Central America: Cancer Drugs Market Share - by Therapy Types
      • 10.6.3.1 South and Central America: Cancer Drugs Market- Revenue and Forecast Analysis - by Therapy Types
    • 10.6.4 South and Central America: Cancer Drugs Market Share - by Indications
      • 10.6.4.1 South and Central America: Cancer Drugs Market- Revenue and Forecast Analysis - by Indications
    • 10.6.5 South and Central America: Cancer Drugs Market Share - by Distribution Channel
      • 10.6.5.1 South and Central America: Cancer Drugs Market- Revenue and Forecast Analysis - by Distribution Channel
    • 10.6.6 South and Central America: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.6.6.1 South and Central America: Cancer Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.6.6.2 Brazil: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.6.6.2.1 Brazil: Cancer Drugs Market Share - by Therapy Types
        • 10.6.6.2.2 Brazil: Cancer Drugs Market Share - by Indications
        • 10.6.6.2.3 Brazil: Cancer Drugs Market Share - by Distribution Channel
      • 10.6.6.3 Argentina: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.6.6.3.1 Argentina: Cancer Drugs Market Share - by Therapy Types
        • 10.6.6.3.2 Argentina: Cancer Drugs Market Share - by Indications
        • 10.6.6.3.3 Argentina: Cancer Drugs Market Share - by Distribution Channel
      • 10.6.6.4 Rest of South and Central America: Cancer Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.6.6.4.1 Rest of South and Central America: Cancer Drugs Market Share - by Therapy Types
        • 10.6.6.4.2 Rest of South and Central America: Cancer Drugs Market Share - by Indications
        • 10.6.6.4.3 Rest of South and Central America: Cancer Drugs Market Share - by Distribution Channel

11. Competitive Landscape

  • 11.1 Heat Map Analysis by Key Players
  • 11.2 Company Positioning and Concentration

12. Industry Landscape

  • 12.1 Overview
  • 12.2 Market Initiative
  • 12.3 Partnerships and Collaborations
  • 12.4 Other Developments

13. Company Profiles

  • 13.1 Bristol-Myers Squibb Co
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 AbbVie Inc
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Astellas Pharma Inc
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Eli Lilly and Co
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Novartis AG
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Merck KGaA
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 AstraZeneca
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Pfizer Inc
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 F. Hoffmann-La Roche Ltd
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Johnson & Johnson
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments

14. Appendix

  • 14.1 About Us
  • 14.2 List of Abbreviations